Paul Schloesser from Endpoints News wrote on Forcefield Therapeutics’ launch following a $6.9m investment in the company from UK life science investor Syncona Limited.
Paul spoke to Richard Francis, CEO, and Dan Gliddon, SVP Early Development, about the science behind Forcefield and how Forcefield is looking at building drugs that can reduce the number of cardiomyocytes being damaged during a heart attack.
About Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd (Forcefield Tx) is a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes. Forcefield Tx was founded by scientists, industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI).
Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by leading FTSE 250 healthcare company, Syncona.